Revenue
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma, Inc. (BBIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | — | — |
| Research & development | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M | $30.6M |
| Operating expenses | — | — | — | — | — | $482.7M | $306.8M | $183.7M | $43.9M |
| Operating income | −$523.4M | −$593.0M | −$607.4M | −$512.2M | −$576.6M | −$474.5M | −$266.2M | −$183.7M | −$43.9M |
| EBITDAderived | −$518.0M | −$586.9M | −$600.9M | −$505.4M | −$570.8M | −$473.0M | −$265.4M | — | — |
| Net income | −$732.9M | −$543.3M | −$653.3M | −$484.7M | −$586.5M | −$505.5M | −$288.6M | −$169.5M | −$43.8M |
| Basic EPSper diluted share | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.90 | -$3.80 | -$2.48 | -$2.12 | -$1.00 |
| Diluted EPSper diluted share | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.90 | -$3.80 | -$2.48 | -$2.12 | -$1.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 37.2K | $70.00 | $2.60M | 8.4K |
| Jun 23, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 2.2K | $68.57 | $150.6K | 8.4K |
| Jun 23, 2026Form 4 · 10b5-1 | Valantine HannahDirector | SellCommon Stock | 2.2K | $68.57 | $150.6K | 9.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Valantine HannahDirector | SellCommon Stock | 2.8K | $68.00 | $190.9K | 11.5K |
| Jun 15, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 1.5K | $67.14 | $100.9K | 6.6K |